DR. ROBERT JOHN DELORENZO, M.D.
Neurology at Marshall St, Richmond, VA

6350479, Feb 26, 2002

Jun 4, 1999

09/325852

Jonnie R. Williams - Manakin-Sabot VA
Robert J. Delorenzo - Richmond VA
Harold R. Burton - Lexington KY

Regent Court Technologies - Town and Country MI

A61K 3578

424751, 424774

The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i. e. , compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinsons disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, antidepression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.

6569470, May 27, 2003

Jan 11, 2002

10/042164

Jonnie R. Williams - Manakin-Sabot VA
Robert J. DeLorenzo - Richmond VA
Harold R. Burton - Lexington KY

Regent Court Technologies, LLC - Town and Country MO

A61K 3578

424751, 424774

The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i. e. , compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinsons disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, anti-depression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.

2005017, Aug 11, 2005

Apr 11, 2005

11/102630

Jonnie Williams - Manakin-Sabot VA, US
Robert DeLorenzo - Richmond VA, US
Harold Burton - Lexington KY, US

Regent Court Technologies - Town and Country MO

A61K031/4439

514343000

The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i.e., compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinson's disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, anti-depression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.

6929811, Aug 16, 2005

Mar 26, 2003

10/396319

Jonnie R. Williams - Manakin-Sabot VA, US
Robert J. DeLorenzo - Richmond VA, US
Harold R. Burton - Lexington KY, US

Regent Court Technologies, LLC - Chesterfield MO

A61K035/78

424751, 424774, 514343

The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i. e. , compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinson's disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, anti-depression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.

2005015, Jul 14, 2005

Dec 10, 2004

11/008258

Robert DeLorenzo - Richmond VA, US

Robert J. DeLorenzo - Richmond VA

A61K031/727, A61K031/375, A61K031/366, A61K031/28, A61K031/573

514056000, 514457000, 514474000, 514492000, 514763000, 514176000, 514179000, 514440000, 514458000

Calcium channels which form in neuronal membranes in response to injury are disclosed. Methods and compositions for blocking this injury induced calcium channel and preventing further injury to neuronal cells and/or neuronal cell death are disclosed. The compositions and methods disclosed may be used to alleviate acute or chronic injury to neuronal cells.